Monograph: |
Di-pot hydrogen citrate
Di-potassium hydrogen citrate is metabolised to
potassium bicarbonate after absorption, thus acting as a
systemic alkaliser.
Di-potassium hydrogen citrate decreases formation of uric
acid and cystine calculi as solubility of uric acid and
cystine increases at high urinary pH. Di-Potassium
hydrogen citrate prevents recurrence of stones after
extracorporeal shock wave lithotripsy. Di-potassium
hydrogen citrate is preferred when administration of
sodium salts is undesirable or contraindicated.
INDICATIONS
β’ Prevention of recurrence of urinary calculi
β’ Relief from pain and burning micturition
β’ Renal tubular acidosis
DOSAGE AND ADMINISTRATION
Adult Dose:
3-5 gms to be taken after meals three times a day, after
being diluted in a glass of water.
Pediatric Dose:
1-2 gms to be taken after meals three times a day, after
being diluted in half a glass of water
CONTRAINDICATIONS
Severe renal impairment with oliguria, untreated Addison's
disease, acute dehydration, severe
myocardial damage, hyperkalemia from any cause and
metabolic or respiratory alkalosis.
PRECAUTIONS
Should be used with caution by patients with low urinary
output. As with all liquids containing
a high concentration of potassium, patients should be
directed to dilute solution adequately as
directed. It is important to check serum potassium level,
pH of urine and blood. ECG may be carried out
during the course of therapy with di-pot hydrogen citrate.
Renal function should be tested during the course of the
therapy at regular intervals. Blood gas analysis and serum
bicarbonate level may be carried out if
required. In patients with signs of urinary tract
infection, urine culture should be done and appropriate
therapy instituted.
WARNING
Large doses may cause hyperkalemia and alkalosis,
especially in the presence of renal disease.
Concurrent administration of potassium containing
medication like URILISER, potassium-sparing
diuretics, angiotensin-converting enzyme inhibitors or
cardiac glycosides may lead to toxicity.
ADVERSE EFFECTS β
Di-pot hydrogen citrate is generally well tolerated without
any unpleasent side effects when given in recommended
doses to patients having normal renal function and urinary
output. However, as with any alkalising agent,
caution must be used in certain patients with renal
impairment to avoid development of hyperkalemia or
alkalosis. Analysis of serum electrolytes may be carried
out periodically to prevent these complications in
such patients.
|